Table 1.

Sensitivity of commercially available test kits and existing biosensors for COVID-19 testing.

Detection method	Sample	Targets	LOD	Ref.
CRISPR technology	Plasma, serum, and throat and nasal swab	-	-	56
	Nasal swab	ORF1ab and N gene	2 copies/sample	57
	Nasopharyngeal swabs	E gene and N gene	10 copies/µL	20
	-	S, N and Orf1ab genes	42 copies/reaction	58
Colorimetric assay	Oropharyngeal swab	N gene	0.18 ng/µL	59
Localized surface plasmon resonance	Synthetic cDNA	RdRp	2.26 × 104 copies	42
RT-LAMP	Swabs and bronchoalveolar lavage fluid	orf1ab	20 copies/reaction	18
		S genes	200 copies/reaction
	Throat swabs	orf1ab	20 copies /25μL	17
		S gene	2 copies/25μL
		N gene	2 copies/25μL
	Nasal swabs	N gene	100 copies	19
DNA nanoscaffold-based hybrid chain reaction	Synthetic RNA	conserved region	0.96 pM	21
RCA	Synthetic cDNA	RdRp	0.4 fM	27
	Nasopharyngeal swab	N gene and S gene	1 copy/µL	This work